

Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation

Carlos Riveros¹, Sanjana Ranganathan¹, Waqar Haque², Emily Huang¹, Jiaqiong Xu³, Girish S. Kulkarni^{4,5}, Michael Geng⁶, Maryam Anis¹, Taliah Muhammad¹, Keith Syson Chan^{1,7}, Andrew Farach², Bin S. Teh², Brian J. Miles¹, Zachary Klaassen⁸, Guru P. Sonpavde⁹, Christopher J.D. Wallis^{4,5,10}, Raj Satkunasivam¹

¹Department of Urology, Houston Methodist Hospital, Houston, TX, United States; ²Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, United States; ³Center for Health Data Science and Analytics, Houston Methodist Hospital, Houston, TX, United States; ⁴Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada; ⁵Division of Urology, University of Toronto, Toronto, ON, Canada; ⁶School of Engineering Medicine, Texas A&M University, Houston, TX, United States; ⁷Center for TME Spatial Profiling in GU Oncology, Houston Methodist Research Institute, Houston, TX, United States; ⁸Division of Urology, Medical College of Georgia, Augusta University, Augusta, GA, United States; ⁹Genitourinary Oncology Program, AdventHealth Cancer Institute, Orlando, FL, United States; ¹⁰Division of Urology, Mount Sinai Hospital, Toronto, ON, Canada

Cite as: Riveros C, Ranganathan S, Haque W, et al. Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation. *Can Urol Assoc J* 2023 October 23; Epub ahead of print. <http://dx.doi.org/10.5489/cuaj.8386>

Published online October 23, 2023

Corresponding author: Dr. Raj Satkunasivam, Department of Urology, Houston Methodist Hospital, Houston, TX, United States; raj.satkunasivam@gmail.com

ABSTRACT

Introduction: Elective pelvic nodal irradiation for patients with muscle-invasive bladder cancer (MIBC) undergoing trimodal therapy (TMT) is controversial. In patients with node-negative (N0) MIBC, the benefit of elective whole-pelvis concurrent chemoradiation (WP-CCR) compared to bladder-only (BO)-CCR has not been demonstrated. Using real-world data from the

KEY MESSAGES

- We sought to explore differences in OS between whole-pelvis and bladder-only concurrent chemoradiation among patients with clinically node negative MIBC using real-world data.
- Using inverse probability treatment weighting-adjusted Cox regression, whole-pelvis concurrent chemoradiation was associated with a significant OS benefit compared to bladder-only concurrent chemoradiation.

National Cancer Database (NCDB), we sought to compare the overall survival (OS) between BO-CCR and WP-CCR for MIBC.

Methods: Using the 2020 NCDB Participant User File, we identified cases of MIBC diagnosed between 2017 and 2019. We selected patients with clinical T2-T4aN0M0 disease receiving CCR as first-line treatment. CCR was defined as transurethral resection of bladder tumor followed by ≥ 40 Gy radiation to the bladder with concurrent single- or multiple-agent chemotherapy. Based on elective nodal irradiation status, patients were stratified as having received BO-CCR vs. WP-CCR. OS analysis was performed using summary three-month conditional landmark, inverse probability treatment weighting (IPTW)-adjusted Kaplan-Meier estimates and Cox regression.

Results: A total of 604 patients receiving CCR for MIBC were identified: 367 (60.8%) BO-CCR and 237 (39.2%) WP-CCR. Before IPTW, the groups were imbalanced in terms of baseline characteristics. The median followup of the weighted population was 42.3 months (interquartile range [IQR] 18.1–49.1 months). In IPTW-adjusted Cox proportional hazards regression analysis, WP-CCR was associated with a significant OS benefit compared to BO-CCR (adjusted hazard ratio 0.72, 95% confidence interval 0.54–0.96, $p=0.026$).

Conclusions: In the setting of CCR for N0 MIBC, this retrospective NCDB analysis revealed that WP-CCR was associated with a benefit in OS compared to BO-CCR.

INTRODUCTION

Bladder cancer is the 10th most frequently diagnosed cancer worldwide, with approximately 573,000 new cases and 213,000 deaths in 2020 [1]. Almost 25% of patients will have muscle-invasive bladder cancer (MIBC) at the time of diagnosis and often undergo radical cystectomy (RC), trimodal therapy (TMT), or palliation. Trimodal therapy entails maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiation (CCR).

Historically, TMT is generally reserved for patients who desire bladder preservation, and for those with significant comorbidities for whom RC is not an option [2]. Several single-arm phase II and phase III trials have provided evidence for the efficacy of TMT [3]. We and others have previously shown TMT as a viable alternative strategy to RC using prospective, propensity score-matched, data from single and multiple institutions [4, 5].

In the absence of neoadjuvant chemotherapy, up to 25% of patients with clinically node-negative (cN0) MIBC are found to have nodal involvement at the time of pelvic lymphadenectomy [6]. The rationale for pelvic lymph node dissection in the setting of RC is supported by multiple studies examining node count and density, all showing reproducibility and consistency [7, 8]. Extrapolating the need to deliver radiation to the nodes is however unclear. Elective pelvic nodal irradiation in the setting of TMT for cN0 MIBC remains controversial [9, 10]. Radiotherapy to the bladder alone already results in significant incidental doses to peripheral

lymph nodes [11]. Whole-pelvis (WP)-CCR has also been associated with higher radiation toxicity and side effects [12]. The role of prophylactic and therapeutic nodal irradiation has been explored in other pelvic malignancies such as prostate and cervical carcinoma [13, 14]. Few studies have compared oncologic outcomes between WP- and bladder-only (BO)-CCR in the setting of TMT for MIBC [15]. Thus, we sought to explore differences in overall survival (OS) between WP- and BO-CCR among patients with cN0 MIBC using real-world data.

METHODS

Data source

The National Cancer Database (NCDB) is a nationwide, facility-based, comprehensive oncology dataset that captures over 70% of all newly diagnosed malignancies in the US annually [16]. Since the data are de-identified, the study was exempt from approval by our institutional review board. This study was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline [17].

Study population

Using the 2020 Urinary Bladder NCDB Participant User File, we identified patients with clinical T2-T4aN0M0 bladder cancer between 2017 and 2019. Based on the International Classification of Diseases for Oncology Third Edition (ICD-O-3) histology codes, we identified patients with urothelial carcinoma (8120/8130) [18]. We selected 2017 as the earliest year for inclusion as it was the year when reporting of “radiation to draining lymph nodes” began [19]. The upper bound was 2019 as it was the latest year for which survival data was available. We excluded patients with unclear radiation volume/dose and those with other malignancies (as they could have received previous radiation or chemotherapy).

Exposure and covariates

Receipt of TMT was defined as having undergone TURBT followed by CCR. Concurrent chemoradiation was defined as radiation to the bladder ≥ 40 Gy [20], in addition to single- or multi-agent chemotherapy. To be considered concurrent, the maximum time interval between the beginning of radiation and chemotherapy was set at 30 days. Radiation could have been delivered in one or two phases. Whole-pelvis radiation was defined as having received concomitant radiation to the bladder and draining pelvic lymph nodes during at least one phase. The following covariates were included: age at diagnosis, sex, race, insurance status, income level, education level, degree of rurality, Charlson-Deyo score, clinical tumor (cT) stage, facility type, and distance to facility (miles).

Outcomes

The primary endpoint of interest was OS. To account for immortal time bias in starting CCR, a three-month landmark was used [21].

Statistical analysis

Patients were stratified into the type of CCR received. Baseline characteristics were abstracted and reported. Continuous variables were expressed as mean with standard deviation (SD) or median with IQR, while categorical variables were reported as proportions and frequencies. Multiple imputation using chained equations was performed to handle missing data assumed to be missing at random for all covariates [22]. The continuous variable for distance to facility was imputed using predictive mean matching with the number of nearest neighbors ($k=5$) [23]. As the recommended number of imputed data sets should be at least as large as the percentage of subjects with any missing data [24], we generated 15 imputed data sets using a sequential regression method. Rubin's rules were utilized to summarize the effect estimates and variances from the 15 different analyses across imputed data sets [25]. We performed multivariable logistic regression analysis to determine predictors of WP-CCR vs BO-CCR receipt.

To account for selection bias, we controlled for observed differences in baseline characteristics between the two treatment groups using inverse probability of treatment weighting (IPTW)-adjusted analyses [26]. Absolute standardized differences (ASD) were reported to assess for baseline differences between the groups and evaluate covariate balance following IPTW. An $ASD > 0.1$ was used to define meaningful imbalance in covariates between treatment groups [27].

Since the median time between diagnosis of MIBC and initiation of CCR was 61 days (interquartile range [IQR]: 47-86 days), summary three-month conditional landmark, IPTW-adjusted Kaplan-Meier estimates were calculated to compare OS between the two groups. Overall median follow-up with IQR was reported for the weighted population. Median IPTW-adjusted OS with corresponding IQR in months were reported for both treatment groups, along with 3-year survival rates. An IPTW-adjusted Cox proportional hazards regression model was computed to evaluate the association between type of CCR treatment and OS. The adjusted hazard ratio (aHR) with its corresponding confidence intervals (CI) was reported. The proportional hazards assumption was assessed globally using a test of weighted Schoenfeld residuals.

Using the IPTW-adjusted Cox proportional hazards regression model, we performed interaction analyses to examine treatment heterogeneity based on age (<65 vs. ≥ 65 years old), sex (male vs. female), insurance status (private vs. government-sponsored [Medicare/Medicaid/Other]), income level (low vs. high), education level (low vs. high), Charlson-Deyo score (0 vs. ≥ 1), cT stage (cT2 vs. cT3-4a), facility type (academic vs. nonacademic), and distance to facility (continuous). Sensitivity analysis with multivariable Cox regression after listwise deletion was performed to assess the robustness of results. All analyses

were performed with STATA version 17 (StataCorp 2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC). Statistical significance was defined as two-tailed $p < 0.05$ for all tests.

RESULTS

A total of 604 patients who received TMT for cT2-4aN0M0 urothelial carcinoma of the bladder were identified; 367 (60.76%) received BO-CCR and 237 (39.24%) received WP-CCR (Figure 1). Unweighted and weighted baseline characteristics of both groups are reported in Table 1. Absolute standardized differences between the unweighted groups indicated imbalance with respect to age, insurance status, rurality, facility type, and distance to facility. Before IPTW, patients in the BO-CCR group were older (mean years, [SD]: 76.5, [8.9] vs. 74.9, [8.5]), less likely to have private insurance (8.17% vs. 15.61%) and live in metropolitan areas (79.29% vs. 83.12%), and more likely to be treated in academic facilities (28.88% vs. 21.94%). In multivariable logistic regression analysis (Table 2), treatment at a nonacademic facility was an independent predictor of WP-CCR receipt (odds ratio [OR] 1.83, [95% CI: 1.15-2.93]), while Medicare insurance was independently associated with nonreceipt of WP-CCR (OR 0.50, [95% CI: 0.26-0.94]).

After IPTW-adjustment, all ASDs were less than 0.1, indicating adequate balance between the two treatment groups. The median follow-up of the weighted population was 42.3 months [IQR: 18.1-49.1 months]. The three-month conditional landmark, IPTW-adjusted Kaplan-Meier curves (Figure 2) showed that median OS was significantly better for WP-CCR (49.1 months, [IQR: 20.8 months-not reached]) vs. BO-CCR (38.9 months, [IQR: 16.7 months-not reached]). The 3-year IPTW-adjusted OS rates were 62.2% for WP-CCR vs. 50.0% for BO-CCR. In IPTW-adjusted Cox proportional hazards regression analysis, WP-CCR was associated with a significant OS benefit compared to BO-CCR (aHR 0.72, [95% CI: 0.54-0.96], $p = 0.026$). Exploratory interaction term analyses demonstrated that the OS benefit of WP-CCR increased significantly with government-sponsored insurance (HR 0.17, [95% CI: 0.03-0.86], $p = 0.032$). No significant interaction was observed with age ($p = 0.9$), sex ($p = 0.5$), income ($p = 0.16$) or education ($p = 0.6$) level, Charlson-Deyo score ($p = 0.6$), cT stage ($p = 0.8$), facility type ($p = 0.2$), or distance to facility ($p = 0.3$). Given the age of eligibility for Medicare, we explored the interaction between age (≥ 65 years old) and insurance status (Medicare) post hoc. However, it was not significant ($p = 0.70$). Sensitivity analysis yielded a similar OS benefit for WP-CCR (aHR 0.66, [95% CI: 0.47-0.93], $p = 0.018$).

DISCUSSION

In the setting of patients receiving TMT for cN0 MIBC, no clear recommendation exists regarding concomitant pelvic nodal irradiation during CCR [10]. As such, we sought to investigate differences in OS between WP- and BO-CCR using real-world data from more than 600 patients. Treatment at a nonacademic facility was associated with receipt of WP-CCR. After

a median follow-up of 42 months, our IPTW-adjusted analysis showed a significant OS benefit for WP-CCR. Specifically, patients who received WP-CCR were 28% less likely to die of any cause compared with patients who received BO-CCR. Although not mature, receipt of WP-CCR translated into a 10-month OS benefit. Interaction analyses revealed that government-sponsored insurance further improved the OS benefit of WP-CCR. Sensitivity analysis demonstrated the robustness of the primary analysis.

Occult nodal involvement despite negative imaging is a common problem among patients with solid tumors. Prophylactic nodal irradiation has shown a benefit in survival outcomes for prostate [28], cervical [29], and breast cancer [30]. In MIBC, despite the absence of randomized data demonstrating the superiority of surgery over TMT [31], radiation with or without concomitant chemotherapy accounts for 8% of treatments in the US [32]. Current guidelines state that CCR is most suitable for patients with solitary tumors, negative nodes, no extensive carcinoma in situ, no tumor-related hydronephrosis, and adequate baseline bladder function [10]. Elective pelvic nodal irradiation during CCR is currently optional for patients with cN0 MIBC as previous trials have not shown a survival benefit [9]. As academic hospitals are more likely to provide guideline-based treatment [33], we hypothesize that this could be why receipt of WP-CCR was less common in these hospitals. Regionalization of care could also explain why treatment at a nonacademic facility was associated with receipt of WP-CCR. Sicker patients generally get referred to academic hospitals [34]; however, they would be less likely to receive WP-CCR due to the greater toxicity associated with larger radiation fields.

A randomized single center trial including 230 patients with cN0 MIBC compared elective WP-CCR (full pelvic volume extending to the L5/S1 interspace superiorly) versus BO-CCR (bladder with 2-cm margins). At a median follow up of 5 years, there were no significant differences in disease-free survival, bladder preservation rates, or OS. In terms of side effects, the overall incidence of grade 3 or 4 acute toxicity was 17.6% in the WP-CCR group vs. 13.3% in the BO-CCR group ($p = 0.05$). The treatment protocol completion rate was 93.1% in the WP-CCR group vs. 95.9% in the BO-CCR group ($p = 0.05$). There were no significant differences in late toxicities between the groups during the 5-year follow up [15]. Compared to our study, the patients in this randomized trial were overall younger, had higher cT stage, and up to 23% did not undergo maximal TURBT prior to CCR. Approximately 54% of patients in the trial by Tunio et al. had \geq cT3 disease, while our cohort only had 7.8% of patients with \geq cT3 disease. Given that cT stage is a predictor of lymph node metastasis [35], it is likely that many patients in the trial had occult lymph node metastasis. Intuitively, this would make BO-CCR a less efficacious option, compared to WP-CCR. This is further supported by the rates of locoregional recurrence reported at five years. The number of patients who experienced regional lymphadenopathy was 42.9% and 45.7% in the WP-CCR and BO-CCR groups, respectively. However, the trial failed to find a significant difference in OS rates between the two groups. The same radiation dose of 65

Gy was used in both groups and there was significant overlap in the radiation fields (≤ 2 cm), which could possibly explain the findings.

Although the results of our study are encouraging, increased toxicity is a major concern in WP-CCR as previously mentioned. Intensity-modulated radiotherapy (IMRT) may provide better sparing of organs at risk and reduce toxicity rates associated with conventional 3D conformal radiation. The single-center phase II Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) trial assessed the feasibility and efficacy of delivering IMRT to the bladder and pelvic nodes. A total of 38 patients (58% and 42% with clinical node positive [cN+] and N0 MIBC, respectively) were recruited, with up to 63% having $>cT2$ disease. The majority of grade 1 or 2 side effects were gastrointestinal (72%), while most grade 3 side effects were genitourinary (21%). The authors attributed the high gastrointestinal toxicity to the concomitant chemotherapy use in 50% of their cohort. At 2 years, there was no reported grade 3 or 4 toxicity. In terms of efficacy, the median OS was 1.9 years, with 2- and 5-year OS rates of 50 and 34%, respectively. An exploratory analysis comparing OS in patients with cN+ and cN0 disease showed no significant difference ($p = 0.62$) [36]. Predictors of occult lymph node involvement might prove useful when deciding between BO- and WP-CCR. A recent study identified lymphovascular invasion as an independent predictor of nodal upstaging (OR 10.1, [95% CI: 2.9-34.9]) [37].

Our results are corroborated by a recent Canadian academic multicenter retrospective inverse probability treatment-weighted analysis of 599 cT2-4aN0-2M0 patients, which reported a survival benefit for WP vs. BO radiotherapy. However, this Canadian study was not exclusive to patients receiving TMT and was performed in select academic centers in contrast to our real-world NCDB study [38]. Finally, the randomized 3-arm phase II RAIDER trial enrolled 345 patients and compared whole bladder RT (WBRT), standard dose adaptive tumor focused RT (SART), and dose escalated adaptive tumor boost RT (DART) for unifocal muscle-invasive node-negative bladder cancer. This trial did not evaluate WP radiotherapy but demonstrated promise for image guided DART [39].

Although Medicare insurance was associated with decreased odds of WP-CCR receipt, government-sponsored insurance was associated with an increase in the OS benefit of WP-CCR. Previous research suggests that Medicare beneficiaries experience fewer problems getting access to care, compared to those with private insurance [40]. It is possible that WP-CCR might be more beneficial for the typical Medicare patient [41]. Nonetheless, in our exploratory interaction analyses, we did not find age or comorbidity burden to affect the OS benefit of WP-CCR. The present study is not without limitations. First, it is retrospective in nature. Second, while higher risk features may lead to selection for WP-CCR, fitter or less frail patients may receive WP-CCR. Third, we could not adjust for relevant covariates such as the specific chemotherapeutic agents used, the specific radiotherapy dosing and fractionation schedules administered, the presence of hydronephrosis, or the completeness of baseline TURBT, as these are not reported in

NCDB. Fourth, we did not have toxicity data or CCR completion rate. Fifth, the OS was not mature given the recency of the variable that was used to identify patients who received pelvic nodal irradiation. Sixth, there could still be confounding bias despite having adjusted for all available relevant covariates. Seventh, we could not evaluate the impact of not having insurance as we did not have uninsured patients in our cohort.

Compared with BO-CCR, the use of WP-CCR for patients with N0 MIBC is associated with an OS benefit. However, these findings must be interpreted with caution as toxicities could not be abstracted, and they may significantly impact quality of life. Further work is required to fully evaluate and select patients for the role of elective nodal irradiation in MIBC.

***Conflict of interest:** The National Cancer Data Base (NCDB) is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society. The CoC's NCDB and the hospitals participating in the CoC NCDB are the source of the de-identified data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.*

DRAFT

REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71:209-49. <https://doi.org/10.3322/caac.21660>
2. Chang SS, Bochner BH, Chou R, et al. Treatment of nonmetastatic muscle-invasive bladder cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology clinical practice guideline summary. *J Oncol Pract*. 2017;13:621-5. <https://doi.org/10.1200/JOP.2017.024919>
3. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. *J Clin Oncol*. 2014;32:3801-9. <https://doi.org/10.1200/JCO.2014.57.5548>
4. Kulkarni GS, Hermanns T, Wei Y, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. *J Clin Oncol* 2017;35:2299-305. <https://doi.org/10.1200/JCO.2016.69.2327>
5. Zlotta AR, Ballas LK, Niemierko A, et al. Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle-invasive bladder cancer. *J Clin Oncol* 2022;40:433-. https://doi.org/10.1200/JCO.2022.40.6_suppl.433
6. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today - A homogeneous series without neoadjuvant therapy. *J Clin Oncol* 2003;21:690-6. <https://doi.org/10.1200/JCO.2003.05.101>
7. Bruins HM, Veskimae E, Hernandez V, et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. *Eur Urol* 2014;66:1065-77. <https://doi.org/10.1016/j.eururo.2014.05.031>
8. Perera M, McGrath S, Sengupta S, et al. Pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer. *Nat Rev Urol* 2018;15:686-92. <https://doi.org/10.1038/s41585-018-0066-1>
9. Dinh TT, Mitin T, Bagshaw HP, et al. Executive summary of the American Radium Society Appropriate Use Criteria for radiation treatment of node-negative muscle-invasive bladder cancer. *Int J Radiat Oncol Biol Phys* 2021;109:953-63. <https://doi.org/10.1016/j.ijrobp.2020.10.031>
10. Flaig T, Spiess P, Agarwal N. NCCN guidelines version 3.2020 bladder cancer. NCCN Evidence Blocks2020.
11. Lewis S, Murthy V, Mahantshetty U, et al. Incidental dose to pelvic nodes in bladder-only radiotherapy: Is it clinically relevant? *Technol Cancer Res Treat* 2017;16:382-7. <https://doi.org/10.1177/1533034617691409>
12. Arafat W, Darwish A, Naoum GE, et al. Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients. *Ecancermedicalscience* 2016;10:682. <https://doi.org/10.3332/ecancer.2016.682>

13. Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas: Ten-year treatment results of RTOG 79-20. *JAMA* 1995;274:387-93. <https://doi.org/10.1001/jama.1995.03530050035029>
14. Vargo JA, Kim H, Choi S, et al. Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era. *Int J Radiat Oncol Biol Phys* 2014;90:1091-8. <https://doi.org/10.1016/j.ijrobp.2014.08.013>
15. Tunio MA, Hashmi A, Qayyum A, et al. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. *Int J Radiat Oncol Biol Phys* 2012;82:e457-62. <https://doi.org/10.1016/j.ijrobp.2011.05.051>
16. Mallin K, Browner A, Palis B, et al. Incident cases captured in the National Cancer Database compared with those in U.S. population-based central cancer registries in 2012-2014. *Ann Surg Oncol* 2019;26:1604-12. <https://doi.org/10.1245/s10434-019-07213-1>
17. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007;147:573-7. <https://doi.org/10.7326/0003-4819-147-8-200710160-00010>
18. Fritz AG. International classification of diseases for oncology : ICD-O. 3rd ed. Geneva: World Health Organization; 2000.
19. American College of Surgeons. National Cancer Database Participant User File 2020 Data Dictionary. 2022.
20. Ritch CR, Balise R, Prakash NS, et al. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer. *BJU Int* 2018;121:745-51. <https://doi.org/10.1111/bju.14109>
21. Yadav K, Lewis RJ. Immortal time bias in observational studies. *JAMA* 2021;325:686-7. <https://doi.org/10.1001/jama.2020.9151>
22. Austin PC, White IR, Lee DS, et al. Missing data in clinical research: A tutorial on multiple imputation. *Can J Cardiol* 2021;37:1322-31. <https://doi.org/10.1016/j.cjca.2020.11.010>
23. Morris TP, White IR, Royston P. Tuning multiple imputation by predictive mean matching and local residual draws. *BMC Med Res Methodol* 2014;14:75. <https://doi.org/10.1186/1471-2288-14-75>
24. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. *Stat Med* 2011;30:377-99. <https://doi.org/10.1002/sim.4067>
25. Little RJ, Rubin DB. Statistical analysis with missing data: *John Wiley & Sons*; 2019. <https://doi.org/10.1002/9781119482260>
26. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. *Stat Med* 2013;32:2837-49. <https://doi.org/10.1002/sim.5705>
27. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Stat Med* 2015;34:3661-79. <https://doi.org/10.1002/sim.6607>

28. De Meerleer G, Berghen C, Briganti A, et al. Elective nodal radiotherapy in prostate cancer. *Lancet Oncol* 2021;22:e348-e57. [https://doi.org/10.1016/S1470-2045\(21\)00242-4](https://doi.org/10.1016/S1470-2045(21)00242-4)
29. Bukkems LJH, Jürgenliemk-Schulz IM, van der Leij F, et al. The impact of para-aortic lymph node irradiation on disease-free survival in patients with cervical cancer: A systematic review and meta-analysis. *Clin Transl Radiat Oncol* 2022;35:97-103. <https://doi.org/10.1016/j.ctro.2022.05.006>
30. Kim YB, Byun HK, Kim DY, et al. Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial. *JAMA Oncol* 2022;8:96-105. <https://doi.org/10.1001/jamaoncol.2021.6036>
31. Huddart RA, Hall E, Lewis R, Birtle A. Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. *BJU Int* 2010;106:753-5. <https://doi.org/10.1111/j.1464-410X.2010.09537.x>
32. Gray PJ, Fedewa SA, Shipley WU, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. *Eur Urol* 2013;63:823-9. <https://doi.org/10.1016/j.eururo.2012.11.015>
33. Washington SL, III, Neuhaus J, Meng MV, et al. Social determinants of appropriate treatment for muscle-invasive bladder cancer. *Cancer Epidemiol Biomarkers Prev* 2019;28:1339-44. <https://doi.org/10.1158/1055-9965.EPI-18-1280>
34. Burke L, Khullar D, Orav EJ, et al. Do academic medical centers disproportionately benefit the sickest patients? *Health Aff (Millwood)* 2018;37:864-72. <https://doi.org/10.1377/hlthaff.2017.1250>
35. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. *Eur Urol* 2006;50:1254-62. <https://doi.org/10.1016/j.eururo.2006.06.010>
36. Tan MP, Harris V, Warren-Oseni K, McDonald F, et al. The intensity-modulated pelvic node and bladder radiotherapy (IMPART) trial: A phase II single-centre prospective study. *Clin Oncol (R Coll Radiol)* 2020;32:93-100. <https://doi.org/10.1016/j.clon.2019.07.017>
37. Saeedian A, Safaei AM, Azimi A, et al. Implications for pelvic lymph node irradiation in definitive chemoradiotherapy of node negative muscle invasive bladder cancer based on predictive factors of clinicopathologic discrepancy. *J Cancer Res Clin Oncol* 2022;149:2537-2542. <https://doi.org/10.1007/s00432-022-04153-4>
38. Kool R, Marcq G, Dragomir A, et al. Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: An inverse probability treatment-weighted analysis. *J Clin Oncol* 2023;41:449. https://doi.org/10.1200/JCO.2023.41.6_suppl.449
39. Huddart RA, Hafeez S, Omar A, et al. Randomised phase II trial of adaptive image guided radiotherapy in muscle invasive bladder cancer: Late toxicity and cancer outcomes. *J Clin Oncol* 2023;41:446. https://doi.org/10.1200/JCO.2023.41.6_suppl.446
40. Davis K, Stremikis K, Doty MM, et al. Medicare beneficiaries less likely to experience cost- and access-related problems than adults with private coverage. *Health Aff (Millwood)* 2012;31:1866-75. <https://doi.org/10.1377/hlthaff.2011.1357>

41. Tarazi W, Welch P, Nguyen N, Bosworth A, Sheingold S, De Lew N, et al. Medicare beneficiary enrollment trends and demographic characteristics. Assistant Secretary for Planning and Evaluation - Office of Health Policy; 2022.

DRAFT

FIGURES AND TABLES


Figure 1. Flowchart for patient selection

Figure 2. Three-month conditional landmark inverse probability of treatment weighting-adjusted Kaplan-Meier estimates of overall survival for patients who received bladder-only concurrent chemoradiation vs. whole-pelvis concurrent chemoradiation in the setting of trimodal therapy for bladder cancer. Risk tables are not shown as data are weighted proportions and not absolute numbers. aHR: adjusted hazard ratio; CI: confidence interval; BO: bladder-only; WP: whole-pelvis; CCR: concurrent chemoradiation




Table 1. Baseline characteristics						
	Unweighted population			Weighted population*		
	BO-CCR	WP-CCR	ASD	BO-CCR	WP-CCR	ASD
	n=367	n=237				
Age at diagnosis, mean [SD]	76.47 [8.92]	74.89 [8.51]	0.181	75.84 [9.23]	75.79 [8.14]	0.005
Sex (%)			0.056			0.001
Male	281 (76.57)	187 (78.90)		77.08	77.12	
Female	86 (23.43)	50 (21.10)		22.92	23.88	
Race (%)			0.061			0.005
White	338 (92.10)	220 (92.83)		92.47	92.73	
Black	21 (5.72)	15 (6.33)		5.84	5.49	
Other	8 (2.18)	2 (0.84)		1.69	1.78	
Insurance status (%)			0.278			0.003
Private insurance	30 (8.17)	37 (15.61)		10.85	10.84	
Medicaid/other government	22 (5.99)	23 (9.70)		7.41	7.26	
Medicare	315 (85.83)	177 (74.68)		81.74	81.9	
Income level (%)			0.001			0.004
Low	147 (40.05)	95 (40.08)		39.56	39.35	
High	220 (59.95)	142 (59.92)		60.44	60.65	
Education level (%)			0.029			0.012
Low	162 (44.14)	108 (45.57)		43.85	43.27	
High	205 (55.86)	129 (54.43)		56.15	56.73	
Rurality (%)			0.103			0.001
Metro	291 (79.29)	197 (83.12)		80.61	80.56	
Urban	73 (19.89)	39 (16.46)		18.73	18.79	
Rural	3 (0.82)	1 (0.42)		0.65	0.65	
Charlson-Deyo score (%)			0.044			0.002
0	214 (58.31)	135 (56.96)		58.29	58.82	
1	65 (17.71)	44 (18.57)		17.55	16.88	
2	43 (11.72)	22 (9.28)		10.90	10.87	
≥3	45 (12.26)	36 (15.19)		13.26	13.43	
Clinical T stage (%)			0.073			0.005
cT2	341 (92.92)	216 (91.14)		91.85	91.63	

cT3	20 (5.45)	15 (6.33)		6.21	6.46	
cT4a	6 (1.63)	6 (2.53)		1.94	1.91	
Facility type (%)			0.16			0.008
Academic	106 (28.88)	52 (21.94)		26.49	26.86	
Non-academic	261 (71.12)	185 (78.06)		73.51	73.14	
Distance to facility in miles, median [IQR]	11.3 [4.9, 28.0]	10.4 [3.3, 24.6]	0.110	10.5 [4.8, 22.1]	10.2 [4.3, 21.9]	0.008

ASD: absolute standardized differences; BO-CCR: bladder-only concurrent chemoradiation; IQR: interquartile range; SD: standard deviation; WP-CCR: whole-pelvis concurrent chemoradiation.

Variable	OR (95% CI)	P
Age at diagnosis	0.99 (0.97–1.01)	0.4
Sex		
Male	1 [reference]	NA
Female	0.89 (0.56–1.41)	0.6
Race		
White	1 [reference]	NA
Black	0.81 (0.36–1.82)	0.6
Other	0.55 (0.10–3.15)	0.5
Insurance status		
Private insurance	1 [reference]	NA
Medicaid/other government	0.99 (0.42–2.33)	1
Medicare	0.50 (0.26–0.94)	0.032
Income level		
Low	1 [reference]	NA
High	0.92 (0.58–1.45)	0.7
Education level		
Low	1 [reference]	NA
High	1.10 (0.70–1.75)	0.7
Rurality		
Metro	1 [reference]	NA
Urban	0.70 (0.41–1.19)	0.19
Rural	0.78 (0.05–13.44)	0.9

Charlson-Deyo score		
0	1 [reference]	NA
1	1.14 (0.68–1.90)	0.6
2	0.80 (0.43–1.51)	0.5
≥3	1.46 (0.83–2.57)	0.19
Clinical T stage		
cT2	1 [reference]	NA
cT3	1.28 (0.68–2.81)	0.5
cT4a	1.49 (0.40–5.48)	0.5
Facility type		
Academic	1 [reference]	NA
Nonacademic	1.83 (1.15–2.93)	0.011
Distance to facility	1.00 (0.99–1.01)	0.7

CI: confidence interval; BO-CCR: bladder-only concurrent chemoradiation; OR: odds ratio; NA: not applicable; WP-CCR: whole-pelvis concurrent chemoradiation.

DRAFT